A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients With Advanced Non-Small Cell Lung Cancer.

Trial Profile

A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients With Advanced Non-Small Cell Lung Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2014

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Gemcitabine (Primary) ; Pemetrexed (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Jun 2012 Planned end date changed from 1 Aug 2013 to 1 Aug 2014 as reported by ClinicalTrials.gov.
    • 04 Jan 2012 Planned end date changed from 1 Aug 2012 to 1 Aug 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top